A Dose Adjusted, Open Label, Multi-Centre Study to Determine the Safety, Tolerability and Pharmacokinetics of STC3141 Administered as an Infusion for up to 72 hours in Subjects with Sepsis and Normal or Compromised Renal Function in an Intensive Care Unit
Latest Information Update: 24 Jun 2021
At a glance
- Drugs STC 314 (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Sponsors Grand Medical Pty Ltd.
- 23 Jun 2021 Status changed from not yet recruiting to recruiting.
- 02 Jul 2020 Status changed from planning to not yet recruiting.
- 28 May 2020 New trial record